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Quantitative structure-activity relationship (QSAR) models are
widely used for in silico prediction of in vivo toxicity of drug
candidates or environmental chemicals, adding value to candidate
selection in drug development or in a search for less hazardous and
more sustainable alternatives for chemicals in commerce. The
development of traditional QSAR models is enabled by numerical
descriptors representing the inherent chemical properties that can
be easily defined for any number of molecules; however, traditional
QSAR models often have limited predictive power due to the lack
of data and complexity of in vivo endpoints. Although it has been
indeed difficult to obtain experimentally derived toxicity data on
a large number of chemicals in the past, the results of quantitative
in vitro screening of thousands of environmental chemicals in
hundreds of experimental systems are now available and continue
to accumulate. In addition, publicly accessible toxicogenomics data
collected on hundreds of chemicals provide another dimension of
molecular information that is potentially useful for predictive
toxicity modeling. These new characteristics of molecular bio-
activity arising from short-term biological assays, i.e., in vitro
screening and/or in vivo toxicogenomics data can now be exploited
in combination with chemical structural information to generate
hybrid QSAR–like quantitative models to predict human toxicity
and carcinogenicity. Using several case studies, we illustrate the
benefits of a hybrid modeling approach, namely improvements in
the accuracy of models, enhanced interpretation of the most
predictive features, and expanded applicability domain for wider
chemical space coverage.
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Computational toxicology is a rapidly growing field that
combines methodologies from computer science, bio and chem-
informatics, chemistry and molecular biology (reviewed by
Kavlock et al., 2008; Nigsch et al., 2009; Rusyn and Daston,
2010). Due to advances in biological screening technologies,
multiple streams of novel toxicological data, ranging from
short-term in vitro assays to various in vivo endpoints, are
available for hundreds of chemicals (Martin et al., 2009; Shukla
et al., 2010). The Tox21 consortium of the U.S. Environmental
Protection Agency (EPA), National Toxicology Program (NTP),
National Institutes of Health Chemical Genomics Center
(NCGC), and U.S. Food and Drug Administration (FDA) is
generating extensive quantitative in vitro data by screening
hundreds to thousands of environmental chemicals in hundreds
of experimental systems with the goal of re-establishing the field
of predictive chemical toxicology under the paradigm of in vitro-
in vivo extrapolation (Collins et al., 2008). Many chemicals have
been screened for toxicity phenotypes in cells from multiple
individuals (Choy et al., 2008; Lock et al., 2012; O’Shea et al.,
2011). In addition, toxicogenomics data collected for hundreds
of chemicals provide another dimension of experimental
knowledge that is potentially useful for predictive chemical
toxicity modeling (Fielden et al., 2007; Uehara et al., 2011).
Innovative frameworks are required to integrate these rich and
diverse new data for systematic investigation of the
determinants of endpoint toxicity, including underlying
chemical, biological, and genetic factors.
The explosive accumulation of biomolecular screening
data that may help explain and predict toxicity mechanisms
has led to the development of novel computational tools
and databases (Barros and Martin, 2008; Blomme et al.,
2009; Fielden et al., 2007; Waters and Fostel, 2004). The
ultimate goal of computational modeling is fast and accurate
estimation of environmental hazards and human health risks
with minimal to no dependence on animal testing (National
Research Council, 2007).
Cheminformatics approaches, such as quantitative structure-
activity relationship (QSAR) modeling, have been traditionally
used to rationalize biological screening data and employ
resulting models, or predictors, as an initial virtual screen for
efficacy and/or safety of candidate chemicals. The availabil-
ity of predictive multidimensional in vitro and/or in vivo
molecular data on a particular compound greatly facilitates
decision making regarding its potential health hazard and
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mechanisms thereof (Roth et al., 2011). However, new
regulations in Europe and initiatives in the United States
(National Research Council, 2007) are applying pressure on the
scientific and risk assessment communities to develop improved
methods for evaluating thousands of chemicals (Rusyn and
Daston, 2010; Schwarzman and Wilson, 2009).
Adverse outcomes in vivo depend both on the chemical’s
structure and the underlying toxicity mechanisms. In tune with
the proliferation of transdisciplinary computational biology
approaches to unravel chemical toxicity mechanisms, this review
highlights several novel integrative strategies for prediction of
in vivo chemical toxicity by concordant exploitation of both
a chemical’s structure and its short-term biological effects.
Several recent studies demonstrate that statistically significant
and externally predictive hybrid models can be developed.
Hybrid modeling also affords a possibility of mechanistic
interpretation both in terms of underlying chemical features and
mechanisms of toxicity. Herein, we describe a general compu-
tational framework for modeling chemical toxicity using
cheminformatics approaches, summarize recent hybrid modeling
methodologies for in vitro-in vivo extrapolation paradigms, and




Chemical structure–based predictors generally fall into two
types: QSAR and expert systems (Valerio, 2009). QSAR are
statistical models linking molecular structures (represented by
chemical descriptors) to an activity such as an adverse health
outcome (e.g., toxicity). QSAR embodies the principle of
similarity, assuming that structurally similar chemicals may also
have closely aligned activities. For example, chemicals with
 0.85 similarity (based on the Tanimoto coefficient) to known
actives were 30 times more likely to be confirmed as active than
those picked randomly (Martin et al., 2002). Expert systems, on
the other hand, are models based on rules determined by the
scientific consensus of the experts. For instance, the Ashby-
Tennant structural alerts for carcinogenicity (Ashby and
Tennant, 1994) have been incorporated into many software
tools (Marchant et al., 2008). There are a number of public and
commercial stand-alone or web-based modeling systems that
have been developed for prediction of a large number of toxicity-
relevant endpoints (Tables 1 and 2). Several recent publications
provide an excellent overview of the computational tools
employed in toxicology (Nigsch et al., 2009; Valerio, 2009).
Although QSAR modeling techniques are under continuous
development, most predictors are not considered to be accurate
enough for estimating complex biological phenotypes (Rusyn
and Daston, 2010). Low quality of data, overextrapolation, and
poor definition of the phenotypes to be predicted have been
identified as factors limiting the accuracy of prediction of
absorption, distribution, metabolism, excretion, and toxicity
endpoints by QSAR (Penzotti et al., 2004; Stouch et al., 2003).
In addition, the inherent limitations of QSAR lie in the general
complexity of factors that impact the ultimate adverse health
effect of a chemical, including pharmacokinetics, temporality,
or the fact that multiple mechanisms and interconnected
molecular signaling pathways may lead to the same toxicity
phenotype. Thus, it is not surprising that the performance of
QSAR models is inversely correlated to the complexity of
the modeled endpoints (Hou and Wang, 2008; Penzotti et al.,
2004), higher accuracy being expected for predicting in vitro
results, and lower accuracy observed for more complex
in vivo endpoints, such as carcinogenicity (Benigni and
Bossa, 2008). Given these limitations, it is unlikely that
significant gains in prediction accuracy would be achieved
by implementing alternative machine learning techniques or
developing new chemical descriptors.
EXPLORING OMICS AND IN VITRO DATA FOR
PREDICTIVE TOXICITY MODELING
Alternative methods have been proposed to improve
predictive accuracy and take into account novel data streams
that may help in overcoming some of the inherent limitations
detailed above. Indeed, mechanistic toxicology research has
taken advantage of technology developments in biomedical
sciences. Toxicogenomics, proteomics, and metabolomics
provide experimental approaches for viewing the complete
biological system that is modulated by a chemical (Ekins et al.,
2005). These complex multidimensional data are now routinely
used in drug and chemical safety evaluation, providing
valuable mechanistic understanding of the molecular changes
associated with the disease or treatment (Cui and Paules, 2010).
The utility of these data in predictive toxicology has also been
explored. A number of studies reported on the development of
models that use omics data (most of these used transcriptional
profiling) to predict chronic toxicity phenotypes (e.g., carcino-
genic potential) with acute or subchronic study–derived
information (Fielden et al., 2007; Uehara et al., 2011) or to
classify chemicals with respect to their potential mode of
toxicity (Fielden et al., 2011; Uehara et al., 2010; Waters et al.,
2010).
Recent advances in automated quantitative high-throughput
screening (qHTS) have generated extensive biological data
that can be modeled using statistical or machine learning
techniques (Shukla et al., 2010). The Tox21 program (Collins
et al., 2008), a partnership between EPA, NTP, NCGC, and
FDA, is leading the field in use of a broad spectrum of in vitro
assays, many in qHTS format, to screen thousands of
environmental chemicals for their potential to disturb bi-
ological pathways that may result in human disease (Xia
et al., 2008). Such data on toxicologically relevant in vitro
endpoints can be utilized as hazard-based triggers to inform
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prioritization for additional testing (Reif et al., 2010), to
predict in vivo toxicity (Martin et al., 2010), or to generate
testable hypotheses concerning the underlying mechanisms of
toxicity (Xia et al., 2009).
Statistical models employing biological data such as gene
signatures or qHTS data as independent variables are in principle
similar to QSAR models because both employ similar
computational tools and focus on predicting similar toxicity
phenotypes (Table 3). Importantly, the biological data–based
models have been shown to be both predictive and interpretable
(Coen, 2010; Van Hummelen and Sasaki, 2010; Wetmore and
Merrick, 2004). Still, pure biological data–based predictive
modeling approaches are not intended to explain chemical-
induced factors but focus on the general biological processes
related to toxicity. Furthermore, such models are inherently
insensitive to explicitly defined chemical features of the tested
compounds, and new biological data must be generated in order
to predict the toxicity of novel compounds. In the case of
biology-based approaches, additional factors such as experi-
mental variability, interpretability, and data acquisition costs also
need to be considered.
HYBRID MODELING APPROACHES
To properly realize the joint benefits of bioinformatics-
and cheminformatics-based approaches, several strategies
can be envisioned (Fig. 1). The simplest approach is to
utilize a ‘‘consensus’’ of QSAR and biological models that
were derived independently to predict the same endpoint
(Fig. 1A). Consensus modeling is an approach to developing an
overall prediction by combining multiple classifiers, and it is
widely used in traditional QSAR (reviewed in Dearden, 2003;
Tong et al., 2006). Proponents of the consensus approach
expound that combining multiple models that otherwise
individually encode for different relationships would result in
a more robust prediction (Tong et al., 2006). On the other hand,
opponents question if the marginal predictivity gains are worth
the added complexity of consensus modeling (Hewitt et al.,
2007). Success of consensus prediction depends on the relative
performance, applicability domain, and the number of included
individual models (Penzotti et al., 2004). Although there are no
published examples of consensus between QSAR and biological
data–based models, this approach is likely to yield models of
predictive performance in between that of contributing models
TABLE 1
Examples of Commercial Toxicity Predictors
Prediction tool Categories of endpointsa Features
ADMET Predictor
www.simulations-plus.com
Irritation and adverse health effects QSAR
Carcinogenicity and genotoxicity
Acute and developmental toxicity
Endocrine disruption and ecotoxicity
ACD/Tox Suite
www.acdlabs.com
Irritation and adverse health effects Confidence intervals and probability of
predictionsGenotoxicity
Acute toxicity
Endocrine disruption and ecotoxicity
DEREK, DEREK Nexus
www.lhasalimited.org











Irritation and adverse health effects Fragment-based QSAR
Carcinogenicity and genotoxicity
Acute and developmental toxicity
Endocrine disruption and ecotoxicity
Leadscope Model Applier
www.leadscope.com
Adverse health effects QSAR
Carcinogenicity
Reproductive and developmental toxicity
HazardExpertPro, ToxAlert
www.compudrug.com
Adverse health effects Expert system
Carcinogenicity and genotoxicity
Developmental toxicity
aIrritation—skin, eye, or lung sensitization, allergies; adverse health effects—organ-specific toxicity; ecotoxicity—aquatic toxicity and related environmental
endpoints.
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as a consequence of statistical averaging. For example, in the
simplest instance, predictions from a QSAR model and
a biological model would be averaged into a final consensus
score. Further improvements in consensus prediction may lie in
adjusting relative contributions of the individual models.
There are several examples of how the modeling routine may
use a ‘‘hierarchical’’ approach (Fig. 1B). First, it was suggested
by several groups that a hierarchy of chemical descriptors of
increased complexity may be used to improve a model’s
accuracy. For instance, Basak et al. (2003) developed models
of cytotoxicity of halocarbons by utilizing a hierarchy of
different types of computed descriptors of inherent chemical
properties. In this method, model building begins with
descriptors, which can be computed most easily, and additional
descriptors that may demand more computational resources are
added only if the easily calculable ones do not give satisfactory
results. A similar approach was incorporated into hierarchical
QSAR (HiT QSAR) software (Kuz’min et al., 2008). Both
studies showed that the complexity of chemical descriptors has
an impact on the accuracy of model predictions.
Second, a hierarchy of computational methods was used,
whereby compounds are classified into subgroups with different
levels of response using liner discriminant analysis followed by
recursive partitioning for each subgroup (Manga et al., 2003).
This study developed a model of drug biotransformation using
physicochemical and structural descriptors to predict the percent
of unmetabolized drug excreted after iv dose. The resultant
hierarchical model for biotransformation was a three-level
decision tree that incorporated various classification techniques
and a series of arbitrary cutoffs.
Third, a hierarchical workflow was proposed to explore
chemical structure/in vitro/in vivo relationships (Zhu et al.,
2009). Under this approach, in vitro/in vivo correlation patterns
for all compounds in the modeling set could be ascertained, and
compounds may be clustered into several subsets (e.g., toxic
both in vitro and in vivo; nontoxic in both cases; toxic in vitro
but nontoxic in vivo) based on the discovered relationships. The
modeling set compounds were partitioned into two or more
subclasses, and a classification QSAR model was developed
using chemical descriptors only. Then, subclass-specific QSAR
models were developed. Thus, for any external compound, the
classification model is used first to make assignment to one of
the subclasses, and then a subclass-specific model is used to
make a quantitative prediction of a compound’s toxicity.
An alternative strategy is a ‘‘hybrid’’ approach (Fig. 1C), in
which biology-derived features and chemical structural properties
are pooled into a joint descriptor matrix, which is then used for
modeling. Although, in principle, such joint descriptors may have
limitations (i.e., data quality, cost of data acquisition, etc.), recent
studies suggest that hybrid descriptors do afford improvement to
the accuracy of prediction of in vivo toxicity. Several recent
publications (Low et al., 2011; Sedykh et al., 2011; Zhu et al.,
2008) provide illustrative examples of hybrid modeling.
For example, Zhu et al. (2008) have introduced a concept of
chemical-biological descriptors where conventional chemical
descriptors are augmented by binary qHTS results (‘‘active’’
response is encoded as ‘‘1,’’ ‘‘inactive’’ as ‘‘0’’) from a variety of
assays to create a single combined array of hybrid descriptors.
Using chemical descriptors only, QSAR modeling resulted in
62.3% prediction accuracy for rodent carcinogenicity applied to
the data set of over 300 chemicals for which rodent 2-year cancer
bioassay data were available. Importantly, the prediction accuracy
of the model was significantly improved (to 72.7%) when
chemical descriptors were augmented by qHTS cytotoxicity data
on six rodent and human cell lines, which were regarded as
biological descriptors.
Sedykh et al. (2011) have employed concentration-response
qHTS data reported by Xia et al. (2008) by transforming them
TABLE 2
Examples of Toxicity Predictors in Public Domain
Prediction tool Categories of endpoints Features
T.E.S.T. (EPA)
www.epa.gov/nrmrl/std/cppb/qsar
Carcinogenicity and genotoxicity Consensus and batch prediction modes by QSAR







Irritation Expert system (ToxTree); QSAR (Lazar); ontology of
toxic endpointsCarcinogenicity and genotoxicity
OECD QSAR Toolbox
www.qsartoolbox.org









Genotoxicity Web-based platform for QSAR modeling or prediction
Ecotoxicity
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into quantitative biological descriptors of chemicals. The in vitro
data, especially concentration-response qHTS profiles, were
shown to improve the results of QSAR modeling of in vivo end
points (i.e., rat LD50) as compared with conventional QSAR
models that used only chemical structure descriptors. Further-
more, the biological qHTS descriptors data also enhanced the
model’s coverage (i.e., the number of compounds within the
applicability domain of the model), which is essential for
applying models to large and diverse chemical libraries of
environmental concern.
Toxicogenomic data provide another example of high-
dimensional biological information that may be used for hybrid
modeling. A comparative analysis of QSAR- and toxicogenom-
ics data–based models was recently reported (Liu et al., 2011).
The authors used gene expression profiles of liver tissue
obtained from rats treated with 62 chemicals at different time
points (1, 3, and 5 days) to predict rat liver carcinogenicity and
concluded that the toxicogenomics data–based models out-
performed QSAR. Low et al. (2011) reported a similar outcome
when gene expression data–based models (24-h rat liver
toxicogenomics profiles of 127 compounds) were compared
with conventional QSAR in modeling 28-day hepatotoxicity in
the rat. However, the latter study also attempted to combine
toxicogenomics data and chemical descriptors for a hybrid
approach. Although hybrid models did not afford prediction
accuracy higher than that of toxicogenomics data–based models,
they identified both chemical features and transcripts predictive
of the phenotype, which provided additional insight regarding
the mechanistic basis of subchronic liver injury.
CONCLUSIONS AND FUTURE DIRECTIONS
Accurate and high-throughput predictive methods are
needed to support efficient decision making regarding the
efficacy and/or safety of candidate compounds and in tiered
screening and assessment schemes. Chemical structure–based
TABLE 3
Examples of Toxicity Data–Based Predictive Models
Predicted endpoints Input variables Publication
Reproductive toxicity 500 in vitro assays on 256 compounds from ToxCast Phase I Martin et al., 2011
Hepatotoxicity Liver gene expression from rats, rat hepatocytes, and human
hepatocytes treated with two compounds for 24 h
Roth et al., 2011
Hepatobiliary injury Blood gene expression and urine metabolomics of rats treated with
16 compounds for 1, 3, 14 days
Ellinger-Ziegelbauer et al., 2011
Hepatotoxicity Liver and blood gene expression of rats treated with eight
compounds at three doses over 6, 24, and 48 h
Huang et al., 2010
Acetaminophen-, phenobarbital- and
methapyrilene-induced hepatotoxicity
Gene expression, proteomics, and metabolomics of mice treated for
short period of time
Coen et al., 2004; Craig et al., 2006;
Waterman et al., 2010
Hepatotoxicity mechanisms Liver gene expression of rats treated with 150 compounds at three
doses from 1 to 28 days
Open TG-GATEs database
(Uehara et al., 2008)
Hepatotoxicity Liver gene expression of rats (rat hepatocytes) treated with 111 (86)
compounds for 24 h




Liver and kidney gene expression of rats treated with 344
compounds for 1–7 days
Iconix database (Blomme et al., 2009;
Fielden et al., 2007; Wang et al., 2008)
Hepatotoxicity Liver gene expression of rats treated with 15 compounds for 6, 24,
and 72 h
Zidek et al., 2007
Nongenotoxic carcinogenicity Liver gene expression of rats treated with 52 compounds for 24 h Nie et al., 2006
Hepatocarcinogenicity Liver gene expression of rats treated with seven congeneric
compounds for 1–28 days
Nakayama et al., 2006
Valproic acid–induced hepatotoxicity Liver gene expression and proteomics and urine metabolomics of
rats treated for 6, 12, and 24 h
Schnackenberg et al., 2006
Toxicity related to pancreas, liver,
kidney, testes, and bladder
Blood and urine metabolomics of rats treated with 147 compounds
for 1–8 days
COMET database (Lindon et al., 2005)
Bromobenzene-induced hepatotoxicity Gene expression and proteomics of rats treated for 6 and 24 h Heijne et al., 2004
Mechanisms of hepatotoxicity Gene expression of rat primary hepatocytes treated with 15
compounds for 24 h
Waring et al., 2001
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predictive methods have been widely applied in the screening
and ranking of thousands of chemicals for bioactivity and
have demonstrated the promise of in silico approaches for
achieving these goals. However, predictive methods based on
chemical structure alone have limitations, especially for
accurately projecting complex in vivo outcomes. Integration
of chemical features and biological screening and/or
toxicogenomic data provides important advantages (i.e.,
improved prediction accuracy, greater chemical space
coverage, and interpretability of predictive features) over
traditional cheminformatic methods such as QSAR modeling.
As shown in Figure 1, novel strategies for integrating
chemical structural information with bioactivity data include
consensus (Tong et al., 2006), hybrid (Sedykh et al., 2011;
Zhu et al., 2008), and hierarchical approaches (Zhu et al.,
2009).
Data limitations are currently the major obstacle to
advancing these transdisciplinary integration approaches. In
particular, the database of toxicity studies is limited to a small
number of chemicals. These chemicals are both too few in
number and too limited in structural diversity for reliable
QSAR analysis. At present, there are only several sufficiently
large omics data sets (e.g., Open Toxicogenomics Project
Genomics Assisted Toxicity Evaluation System [http://toxico.
nibio.go.jp/], Chemical Effects in Biological Systems Database
[http://www.niehs.nih.gov/research/resources/databases/cebs/],
ToxExpress [http://www.genelogic.com/knowledge-suites/
toxexpress-program]) with hundreds of compounds of largely
disparate chemotypes selected for phenotypic diversity. As such,
most omics data sets are poorly suited for machine learning by
QSAR. This deficit supports the more general and recognized
need for hazard characterization of a greater number of more
varied chemicals, including a larger proportion of the tens of
thousands of yet untested chemicals in commerce and the
environment. Other outstanding data needs concern the classifi-
cation of chemicals according to a wider array of hazard traits and
susceptibility factors (Guyton et al., 2009). There are ongoing
efforts to address these significant data limitations by character-
izing multiple in vitro and in vivo toxicological phenotypes
(Martin et al., 2009; Padilla et al., 2012; Shukla et al., 2010),
including in cells from genetically diverse individuals (Choy
et al., 2008; Lock et al., 2012; O’Shea et al., 2011). The large-
scale screening efforts of Tox21 (Huang et al., 2011) and other
public-private partnerships (Cavero, 2011) hold particular promise
for vastly expanding the database of chemicals and endpoints for
which experimental data are available.
Additional types of hybrid/hierarchical modeling approaches
can be envisioned to address the dependency of hybrid
approaches on the availability of experimental data, a current
limitation for the wide use of these models in predictive
FIG. 1. Strategies for utilizing biological and chemical data in predictive modeling of in vivo toxicity.
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toxicology. In principle, QSAR models could be developed
to predict the results of short-term toxicity assays (once enough
data for a sufficiently large chemical library is available)
because this task is inherently less challenging than modeling
complex in vivo endpoints. This represents an intriguing
possibility of applying QSAR methods to build predictive
models of each of many individual molecular endpoints from
which the resulting ‘‘predicted in vitro’’ data can then be used
as inputs into models of in vivo toxicity (Martin et al., 2011;
Sipes et al., 2011). The application of this strategy could
potentially enable a predictive modeling workflow that does
not require new experimental data and employs only compound
descriptors that can be computed from chemical structure.
Future computational methods should aim to optimize the
use of both chemical- and biological-based data domains to
achieve the most accurate predictions possible, because each
one individually provides limited and complementary insights
regarding toxicity. To this end, studies can be designed with
both approaches in mind, so as to provide sufficient diversity
from both chemical and biological data domains. The goal
should be to generate data matrices with broad and dense
coverage of chemical structure and bioactivities for hybrid data
analysis, i.e., combining chemical and biological data for
machine learning. Additional improvements can be achieved
by using mechanistically relevant short-term toxicity assays.
The resulting integrative approaches have the potential to
become a powerful tool for elucidating both relevant bio-
logical interactions and structural motifs that together better
represent the underlying complex mechanisms by which toxic
effects of chemicals develop. Systematic investigation of
genetic and other determinants of chemical toxicity can
also be envisioned. These approaches can, in turn, support
applications in the design of new products and chemical
processes as well as in the evaluation of in-use chemicals and
environmental contaminants, based on comprehensive and
integrative characterization by both chemical structural features
and the results of multiple and diverse short-term biological
assays and/or omics studies.
FUNDING
This work was supported, in part, by grants from the
National Institutes of Health (NIH) (R01 ES015241) and U.S.
Environmental Protection Agency (EPA) (RD83382501).
ACKNOWLEDGMENTS
The research described in this article has not been subjected
to each funding agency’s peer review and policy review and
therefore does not necessarily reflect their views and no official
endorsement should be inferred. The authors declare no
competing financial interests.
REFERENCES
Ashby, J., and Tennant, R. W. (1994). Prediction of rodent carcinogenicity for
44 chemicals: Results. Mutagenesis 9, 7–15.
Barros, S. A., and Martin, R. B. (2008). Predictive toxicogenomics in
preclinical discovery. Methods Mol. Biol. 460, 89–112.
Basak, S. C., Balasubramanian, K., Gute, B. D., Mills, D., Gorczynska, A., and
Roszak, S. (2003). Prediction of cellular toxicity of halocarbons from
computed chemodescriptors: A hierarchical QSAR approach. J. Chem. Inf.
Comput. Sci. 43, 1103–1109.
Benigni, R., and Bossa, C. (2008). Predictivity and reliability of QSAR models:
The case of mutagens and carcinogens. Toxicol. Mech. Methods 18, 137–147.
Blomme, E. A., Yang, Y., and Waring, J. F. (2009). Use of toxicogenomics to
understand mechanisms of drug-induced hepatotoxicity during drug
discovery and development. Toxicol. Lett. 186, 22–31.
Cavero, I. (2011). Promises and partnership: FDA’s Critical Path Initiative and
its intersection with pharmacology: An ASPET 2011 annual meeting
symposium. Expert Opin. Drug Saf. 10, 827–837.
Choy, E., Yelensky, R., Bonakdar, S., Plenge, R. M., Saxena, R.,
De Jager, P. L., Shaw, S. Y., Wolfish, C. S., Slavik, J. M., et al. (2008).
Genetic analysis of human traits in vitro: Drug response and gene expression
in lymphoblastoid cell lines. PLoS Genet. 4, e1000287.
Coen, M. (2010). A metabonomic approach for mechanistic exploration of
pre-clinical toxicology. Toxicology 278, 326–340.
Coen, M., Ruepp, S. U., Lindon, J. C., Nicholson, J. K., Pognan, F.,
Lenz, E. M., and Wilson, I. D. (2004). Integrated application of
transcriptomics and metabonomics yields new insight into the toxicity due
to paracetamol in the mouse. J. Pharm. Biomed. Anal. 35, 93–105.
Collins, F. S., Gray, G. M., and Bucher, J. R. (2008). Toxicology.
Transforming environmental health protection. Science 319, 906–907.
Craig, A., Sidaway, J., Holmes, E., Orton, T., Jackson, D., Rowlinson, R.,
Nickson, J., Tonge, R., Wilson, I., and Nicholson, J. (2006). Systems
toxicology: Integrated genomic, proteomic and metabonomic analysis of
methapyrilene-induced hepatotoxicity in the rat. J. Proteome Res. 5, 1586–1601.
Cui, Y., and Paules, R. S. (2010). Use of transcriptomics in understanding
mechanisms of drug-induced toxicity. Pharmacogenomics 11, 573–585.
Dearden, J. C. (2003). In silico prediction of drug toxicity. J. Comput. Aided
Mol. Des. 17, 119–127.
Ekins, S., Nikolsky, Y., and Nikolskaya, T. (2005). Techniques: Application of
systems biology to absorption, distribution, metabolism, excretion and
toxicity. Trends Pharmacol. Sci. 26, 202–209.
Ellinger-Ziegelbauer, H., Adler, M., Amberg, A., Brandenburg, A.,
Callanan, J. J., Connor, S., Fountoulakis, M., Gmuender, H., Gruhler, A.,
Hewitt, P., et al. (2011). The enhanced value of combining conventional and
‘‘omics’’ analyses in early assessment of drug-induced hepatobiliary injury.
Toxicol. Appl. Pharmacol. 252, 97–111.
Fielden, M. R., Adai, A., Dunn, R. T., Olaharski, A., Searfoss, G., Sina, J.,
Aubrecht, J., Boitier, E., Nioi, P., Auerbach, S., et al. (2011). Development and
evaluation of a genomic signature for the prediction and mechanistic assessment
of nongenotoxic hepatocarcinogens in the rat. Toxicol. Sci. 124, 54–74.
Fielden, M. R., Brennan, R., and Gollub, J. (2007). A gene expression
biomarker provides early prediction and mechanistic assessment of hepatic
tumor induction by nongenotoxic chemicals. Toxicol. Sci. 99, 90–100.
Guyton, K. Z., Kyle, A. D., Aubrecht, J., Cogliano, V. J., Eastmond, D. A.,
Jackson, M., Keshava, N., Sandy, M. S., Sonowane, B., Zhang, L., et al.
(2009). Improving prediction of chemical carcinogenicity by considering
multiple mechanisms and applying toxicogenomic approaches. Mutat. Res.
681, 230–240.
Heijne, W. H., Slitt, A. L., van Bladeren, P. J., Groten, J. P., Klaassen, C. D.,
Stierum, R. H., and Van Ommen, B. (2004). Bromobenzene-induced
hepatotoxicity at the transcriptome level. Toxicol. Sci. 79, 411–422.
INTEGRATING CHEMISTRY AND BIOLOGY IN MODELING 7
Hewitt, M., Cronin, M. T., Madden, J. C., Rowe, P. H., Johnson, C., Obi, A.,
and Enoch, S. J. (2007). Consensus QSAR models: Do the benefits outweigh
the complexity? J. Chem. Inf. Model. 47, 1460–1468.
Hou, T., and Wang, J. (2008). Structure-ADME relationship: Still a long way to
go? Expert Opin. Drug Metab. Toxicol. 4, 759–770.
Huang, J., Shi, W., Zhang, J., Chou, J. W., Paules, R. S., Gerrish, K., Li, J.,
Luo, J., Wolfinger, R. D., Bao, W., et al. (2010). Genomic indicators in
the blood predict drug-induced liver injury. Pharmacogenomics J. 10,
267–277.
Huang, R., Xia, M., Cho, M. H., Sakamuru, S., Shinn, P., Houck, K. A.,
Dix, D. J., Judson, R. S., Witt, K. L., Kavlock, R. J., et al. (2011). Chemical
genomics profiling of environmental chemical modulation of human nuclear
receptors. Environ. Health Perspect. 119, 1142–1148.
Kavlock, R. J., Ankley, G., Blancato, J., Breen, M., Conolly, R., Dix, D.,
Houck, K., Hubal, E., Judson, R., Rabinowitz, J., et al. (2008).
Computational toxicology—A state of the science mini review. Toxicol.
Sci. 103, 14–27.
Kuz’min, V. E., Artemenko, A. G., and Muratov, E. N. (2008). Hierarchical
QSAR technology based on the Simplex representation of molecular
structure. J. Comput. Aided Mol. Des. 22, 403–421.
Lindon, J. C., Keun, H. C., Ebbels, T. M., Pearce, J. M., Holmes, E., and
Nicholson, J. K. (2005). The Consortium for Metabonomic Toxicology
(COMET): Aims, activities and achievements. Pharmacogenomics 6,
691–699.
Liu, Z., Kelly, R., Fang, H., Ding, D., and Tong, W. (2011). Comparative
analysis of predictive models for nongenotoxic hepatocarcinogenicity using
both toxicogenomics and quantitative structure-activity relationships. Chem.
Res. Toxicol. 24, 1062–1070.
Lock, E. F., Abdo, N., Huang, R., Xia, M., O’Shea, S. H., Zhou, Y. H.,
Sedykh, A., Tropsha, A., Austin, C. P., Tice, R. R., et al. (2012).
Quantitative high-throughput screening for chemical toxicity in a population-
based in vitro model. Toxicol. Sci. 126, 578–588.
Low, Y., Uehara, T., Minowa, Y., Yamada, H., Ohno, Y., Urushidani, T.,
Sedykh, A., Muratov, E. N., Kuz’min, V., Fourches, D., et al. (2011).
Predicting drug-induced hepatotoxicity using QSAR and toxicogenomics
approaches. Chem. Res. Toxicol. 24, 1251–1262.
Manga, N., Duffy, J. C., Rowe, P. H., and Cronin, M. T. (2003). A hierarchical
QSAR model for urinary excretion of drugs in humans as a predictive tool
for biotransformation. QSAR Comb. Sci. 22, 263–273.
Marchant, C. A., Briggs, K. A., and Long, A. (2008). In silico tools for sharing
data and knowledge on toxicity and metabolism: Derek for windows, meteor,
and vitic. Toxicol. Mech. Methods 18, 177–187.
Martin, M. T., Dix, D. J., Judson, R. S., Kavlock, R. J., Reif, D. M.,
Richard, A. M., Rotroff, D. M., Romanov, S., Medvedev, A.,
Poltoratskaya, N., et al. (2010). Impact of environmental chemicals on key
transcription regulators and correlation to toxicity end points within EPA’s
ToxCast program. Chem. Res. Toxicol. 23, 578–590.
Martin, M. T., Judson, R. S., Reif, D. M., Kavlock, R. J., and Dix, D. J. (2009).
Profiling chemicals based on chronic toxicity results from the U.S. EPA
ToxRef Database. Environ. Health Perspect. 117, 392–399.
Martin, M. T., Knudsen, T. B., Reif, D. M., Houck, K. A., Judson, R. S.,
Kavlock, R. J., and Dix, D. J. (2011). Predictive model of rat reproductive
toxicity from ToxCast high throughput screening. Biol. Reprod. 85,
327–339.
Martin, Y. C., Kofton, J. L., and Traphagen, L. M. (2002). Do structurally
similar molecules have similar biological activity? J. Med. Chem. 45,
4350–4358.
Nakayama, K., Kawano, Y., Kawakami, Y., Moriwaki, N., Sekijima, M.,
Otsuka, M., Yakabe, Y., Miyaura, H., Saito, K., Sumida, K., et al. (2006).
Differences in gene expression profiles in the liver between carcino-
genic and non-carcinogenic isomers of compounds given to rats in a
28-day repeat-dose toxicity study. Toxicol. Appl. Pharmacol. 217,
299–307.
National Research Council (2007). Toxicity Testing in the 21st Century:
A Vision and a Strategy. National Academies Press, Washington, DC.
Nie, A. Y., McMillian, M., Parker, J. B., Leone, A., Bryant, S., Yieh, L.,
Bittner, A., Nelson, J., Carmen, A., Wan, J., et al. (2006). Predictive
toxicogenomics approaches reveal underlying molecular mechanisms of
nongenotoxic carcinogenicity. Mol. Carcinog. 45, 914–933.
Nigsch, F., Macaluso, N. J., Mitchell, J. B., and Zmuidinavicius, D. (2009).
Computational toxicology: An overview of the sources of data and of
modelling methods. Expert Opin. Drug Metab. Toxicol. 5, 1–14.
O’Shea, S. H., Schwarz, J., Kosyk, O., Ross, P. K., Ha, M. J., Wright, F. A.,
and Rusyn, I. (2011). In vitro screening for population variability in chemical
toxicity. Toxicol. Sci. 119, 398–407.
Padilla, S., Corum, D., Padnos, B., Hunter, D. L., Beam, A., Houck, K. A.,
Sipes, N., Kleinstreuer, N., Knudson, T., Dix, D. J., et al. (2012). Zebrafish
developmental screening of the ToxCast Phase I chemical library. Reprod.
Toxicol. 33, 174–187.
Penzotti, J. E., Landrum, G. A., and Putta, S. (2004). Building predictive
ADMET models for early decisions in drug discovery. Curr. Opin. Drug
Discov. Devel. 7, 49–61.
Reif, D. M., Martin, M. T., Tan, S. W., Houck, K. A., Judson, R. S.,
Richard, A. M., Knudsen, T. B., Dix, D. J., and Kavlock, R. J. (2010).
Endocrine profiling and prioritization of environmental chemicals using
ToxCast data. Environ. Health Perspect. 118, 1714–1720.
Roth, A., Boess, F., Landes, C., Steiner, G., Freichel, C., Plancher, J. M.,
Raab, S., de Vera Mudry, C., Weiser, T., and Suter, L. (2011). Gene
expression-based in vivo and in vitro prediction of liver toxicity allows
compound selection at an early stage of drug development. J. Biochem. Mol.
Toxicol. 25, 183–194.
Rusyn, I., and Daston, G. P. (2010). Computational toxicology: Realizing the
promise of the toxicity testing in the 21st century. Environ. Health Perspect.
118, 1047–1050.
Schnackenberg, L. K., Jones, R. C., Thyparambil, S., Taylor, J. T., Han, T.,
Tong, W., Hansen, D. K., Fuscoe, J. C., Edmondson, R. D., Beger, R. D.,
et al. (2006). An integrated study of acute effects of valproic acid in the liver
using metabonomics, proteomics, and transcriptomics platforms. OMICS 10,
1–14.
Schwarzman, M. R., and Wilson, M. P. (2009). New science for chemicals
policy. Science 326, 1065–1066.
Sedykh, A., Zhu, H., Tang, H., Zhang, L., Richard, A., Rusyn, I., and
Tropsha, A. (2011). Use of in vitro HTS-derived concentration-response data
as biological descriptors improves the accuracy of QSAR models of in vivo
toxicity. Environ. Health Perspect. 119, 364–370.
Shukla, S. J., Huang, R., Austin, C. P., and Xia, M. (2010). The future of
toxicity testing: A focus on in vitro methods using a quantitative high-
throughput screening platform. Drug Discov. Today 15, 997–1007.
Sipes, N. S., Martin, M. T., Reif, D. M., Kleinstreuer, N. C., Judson, R. S.,
Singh, A. V., Chandler, K. J., Dix, D. J., Kavlock, R. J., and
Knudsen, T. B. (2011). Predictive models of prenatal developmental
toxicity from ToxCast high-throughput screening data. Toxicol. Sci. 124,
109–127.
Stouch, T. R., Kenyon, J. R., Johnson, S. R., Chen, X. Q., Doweyko, A., and
Li, Y. (2003). In silico ADME/Tox: Why models fail. J Comput. Aided Mol.
Des. 17, 83–92.
Tong, W., Fang, H., Xie, Q., Hong, H., Shi, L., Perkins, R., Scherf, U.,
Goodsaid, F., and Frueh, F. W. (2006). Gaining confidence on molecular
classification through consensus modeling and validation. Toxicol. Mech.
Methods 16, 59–68.
Uehara, T., Hirode, M., Ono, A., Kiyosawa, N., Omura, K., Shimizu, T.,
Mizukawa, Y., Miyagishima, T., Nagao, T., and Urushidani, T. (2008).
8 RUSYN ET AL.
A toxicogenomics approach for early assessment of potential non-genotoxic
hepatocarcinogenicity of chemicals in rats. Toxicology 250, 15–26.
Uehara, T., Minowa, Y., Morikawa, Y., Kondo, C., Maruyama, T., Kato, I.,
Nakatsu, N., Igarashi, Y., Ono, A., Hayashi, H., et al. (2011). Prediction
model of potential hepatocarcinogenicity of rat hepatocarcinogens using
a large-scale toxicogenomics database. Toxicol. Appl. Pharmacol. 255,
297–306.
Uehara, T., Ono, A., Maruyama, T., Kato, I., Yamada, H., Ohno, Y., and
Urushidani, T. (2010). The Japanese toxicogenomics project: Application of
toxicogenomics. Mol. Nutr. Food Res. 54, 218–227.
Valerio, L. G. J. (2009). In silico toxicology for the pharmaceutical sciences.
Toxicol. Appl. Pharmacol. 241, 356–370.
Van Hummelen, P., and Sasaki, J. (2010). State-of-the-art genomics approaches
in toxicology. Mutat. Res. 705, 165–171.
Wang, E. J., Snyder, R. D., Fielden, M. R., Smith, R. J., and Gu, Y. Z. (2008).
Validation of putative genomic biomarkers of nephrotoxicity in rats.
Toxicology 246, 91–100.
Waring, J. F., Ciurlionis, R., Jolly, R. A., Heindel, M., and Ulrich, R. G. (2001).
Microarray analysis of hepatotoxins in vitro reveals a correlation between gene
expression profiles and mechanisms of toxicity. Toxicol. Lett. 120, 359–368.
Waterman, C. L., Currie, R. A., Cottrell, L. A., Dow, J., Wright, J.,
Waterfield, C. J., and Griffin, J. L. (2010). An integrated functional genomic
study of acute phenobarbital exposure in the rat. BMC Genomics 11, 9.
Waters, M. D., and Fostel, J. M. (2004). Toxicogenomics and systems
toxicology: Aims and prospects. Nat. Rev. Genet. 5, 936–948.
Waters, M. D., Jackson, M., and Lea, I. (2010). Characterizing and predicting
carcinogenicity and mode of action using conventional and toxicogenomics
methods. Mutat. Res. 705, 184–200.
Wetmore, B. A., and Merrick, B. A. (2004). Toxicoproteomics: Proteomics
applied to toxicology and pathology. Toxicol. Pathol. 32, 619–642.
Xia, M., Huang, R., Guo, V., Southall, N., Cho, M. H., Inglese, J.,
Austin, C. P., and Nirenberg, M. (2009). Identification of compounds that
potentiate CREB signaling as possible enhancers of long-term memory.
Proc. Natl. Acad. Sci. U.S.A. 106, 2412–2417.
Xia, M., Huang, R., Witt, K. L., Southall, N., Fostel, J., Cho, M. H., Jadhav, A.,
Smith, C. S., Inglese, J., Portier, C. J., et al. (2008). Compound cytotoxicity
profiling using quantitative high-throughput screening. Environ. Health
Perspect. 116, 284–291.
Zhu, H., Rusyn, I., Richard, A., and Tropsha, A. (2008). Use of cell viability
assay data improves the prediction accuracy of conventional quantitative
structure-activity relationship models of animal carcinogenicity. Environ.
Health Perspect. 116, 506–513.
Zhu, H., Ye, L., Richard, A., Golbraikh, A., Wright, F. A., Rusyn, I., and
Tropsha, A. (2009). A novel two-step hierarchical quantitative structure-
activity relationship modeling work flow for predicting acute
toxicity of chemicals in rodents. Environ. Health Perspect. 117,
1257–1264.
Zidek, N., Hellmann, J., Kramer, P. J., and Hewitt, P. G. (2007). Acute
hepatotoxicity: A predictive model based on focused Illumina microarrays.
Toxicol. Sci. 99, 289–302.
INTEGRATING CHEMISTRY AND BIOLOGY IN MODELING 9
